| Sonstiges: |
- Nachgewiesen in: USPTO Patent Applications
- Sprachen: English
- Document Number: 20180162846
- Publication Date: June 14, 2018
- Appl. No: 15/674230
- Application Filed: August 10, 2017
- Claim: 1.-10. (canceled)
- Claim: 11. A pharmaceutical composition comprising a compound of claim 1, having formula (Ie) [chemical expression included] or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient, wherein R1 is a member selected from the group consisting of hydrogen, C1-8 alkyl, C1-8 haloalkyl, C1-8 hydroxyalkyl, C3-8 cycloalkyl, halogen, —CN, —SO2Me and —C(O)NH2; each R2 is a member selected from the group consisting of C1-8 alkyl, C1-8 haloalkyl, halogen, —CN and C1-8 alkoxy; R4 is a member selected from the group consisting of hydrogen, C1-8 alkyl, C1-8 haloalkyl and C1-8 hydroxyalkyl; the subscripts n is independently an integer from 0 to 3; Q is a member selected from the group consisting of C and N; Y and Z are independently selected from the group consisting of CH and N; R6 is selected from the group consisting of H, —OH, C1-8 alkyl, C1-8 hydroxyalkyl, C1-4 alkoxy-C1-4 alkyl, —C(O)NRaRb, C1-8 alkylene-C(O)NRaRb, —NH—C1-4 alkylene-C(O)NRaRb, —C(O)—C1-4 alkylene-NRaRb, —CO2H, C1-8 alkylene-CO2H, —N(Ra)C(O)NRaRb, C1-8 alkylene N(Ra)C(O)NRaRb, —NRaRb, C1-8 alkylene-NRaRb, C1-8 alkoxy, —C(O)ORa, C1-8 alkylene-C(O)ORa, —CN, —C(O)Ra, —SO2Ra and —N(Ra)C(O)Rb, wherein each Ra and Rb are independently selected from the group consisting of hydrogen, C1-8 alkyl, C1-8 hydroxyalkyl, C1-8 haloalkyl, and C1-8 alkoxy; and R7 is absent or is selected from the group consisting of H, C1-8 alkyl and C1-8 haloalkyl.
- Claim: 12. A pharmaceutical composition of claim 11, wherein n is 1, and R4 is hydrogen or methyl.
- Claim: 13. A pharmaceutical composition of claim 11, having formula (If): [chemical expression included] wherein each R2 is a member selected from the group consisting of C1-8 alkyl, C1-8 haloalkyl, halogen and —CN.
- Claim: 14. (canceled)
- Claim: 15. A pharmaceutical composition of claim 11, wherein the ring having Z as a ring vertex is selected from the group consisting of pyrrolidine and piperidine.
- Claim: 16. A pharmaceutical composition of claim 11, wherein the ring having Z as a ring vertex is selected from the group consisting of pyrrolidin-2-yl and piperidin-2-yl, and at least one of R6 and R7 is other than hydrogen.
- Claim: 17.-23. (canceled)
- Claim: 24. A pharmaceutical composition in accordance with claim 11, wherein said compound is [chemical expression included] or a pharmaceutically acceptable salt thereof.
- Claim: 25. A pharmaceutical composition in accordance with claim 11, wherein said compound is [chemical expression included] or a pharmaceutically acceptable salt thereof.
- Claim: 26. (canceled)
- Claim: 27. A method of treating a disease or condition mediated by CCR(4) signalling, said method comprising administering to a subject in need thereof an efficacious amount of a compound selected from the group consisting of [chemical expression included]
- Claim: 28. A method in accordance with claim 27, wherein said disease or condition is selected from the group consisting of (1) allergic diseases, (2) inflammatory bowel diseases, (3) vaginitis, (4) psoriasis and inflammatory dermatoses, (5) vasculitis, (6) spondyloarthropathies, (7) scleroderma, (8) asthma and respiratory allergic diseases, (9) autoimmune diseases, (10) graft rejection, (11) other diseases in which undesired inflammatory responses are to be inhibited, and cancer.
- Claim: 29. A method in accordance with claim 27, wherein said disease or condition is selected from the group consisting of allergic diseases, psoriasis, atopic dermatitis and asthma.
- Claim: 30. (canceled)
- Claim: 31. (canceled)
- Current International Class: 07; 61; 07; 61; 61; 61; 61; 07; 07; 07; 07; 07; 07; 07; 07; 07; 07; 07; 07; 61
|
